Whistleblower!

After the provisions in the whistle blower act, pharma has seen many illegal marketing tactics coming out in public, Pfizer has been targeted many a times and it’s still with its competitor Novartis considered the best in the field of Pharma Marketing

We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?

Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.

As whistleblower act has been promoted in US we have more to watch!

Teva will it follow the BMS way?

After the investor's day update last week that Teva will be saving around USD 2 Billion of cash going forward. Mr Jermy levin has started implementing the process. Today Teva announced that its scrapping a $300 million warehouse project in Philadelphia has been halted.

Levin recently laid out a 5-year plan to diversify the company's products and to save up to $2 billion in large part by making its manufacturing operations more efficient. 

In light of the evaluation, a spokesperson said in an emailed statement, "As such, we have made the decision to cease development plans for the proposed distribution center on Red Lion Road in Philadelphia. At this time we cannot elaborate further about plans for this property."

What will be interesting going forward that there will be more possibility that Teva will also collaborate with some big Asian generic/biopharma companies for small molecule development the same lines BMS did with research outsourcing to India based Biocon some years back..... As he was key stakeholder involved in the famous BMS- Biocon alliance in India. Will Jermy move that way only time will say? 

CRO's New Marketing game!

Today at one side I have been down with fever but one promotion by Quintiles intrigued me " Quintiles: your RA partner"


RA landscape has been the most interesting landscape both in terms of small molecules and bio generics....Abbott had already been a market leader in terms of Humira but Pfizer has big plans for capturing the market share and we need to look at how it’s going to go for its pricing so that it has quick approval from the regulatory bodies in European region...
Now we need to just see if quintiles is going to be trials partner for the major companies who are investing in this segment for both the big daddy’s and bio generics and generic manufacturers in the RA landscape as compared to oncology its comparative easy market entry......What will be the next strategy for Icon, Paraxel, PPD and convance?

Teva the giant......Will it be major contributor in Pharma Consolidation?

Jermy Levin became a Teva CEO long time back and I think has completed his probation period. Teva as a company is very conservation on its approach in advancement in any particular space in terms of indication attractiveness and product opportunities. After long time I was hearing Jermy Levin speak about its move....Teva for some time has been dwindling in a particular frame of mind as being a generic player or move differently the innovative path. What I am very positive about is that Jermy Levin was one of kind who made difference for BMS and i hope that he will have better success story to be told in future for Teva.........Teva like Novartis will be a one of the key player of the next Pharma consolidation happening by year 2020

Sanofi with New MENA Strategy!

Some one year back I wrote about companies like Merck and Novartis opening their shop floors in Turkey and how Turkey going forward is becoming a hot destination  for drug marketing and promotion, in a recent progress Sanofi is looking for acquisition of Czech company Zentiva which is worth $2.6 Billion , the deal will help Sanofi accelerate its presence in the MENA region as Zentiva has strong presence in the region….last month there were update for Biosimilar development by companies for MENA region…..after India and China ……MENA is the next favorable destination going forward

MENA: Middle East and North Africa

Will these two drugs save Pfizer????

In year 2012 I will consider November as the best month for Pfizer as it has got approval for two important drugs which the analyst and the scientists believe that will mark a difference for Pfizer in terms of the blockbuster game, though now a days in the pharma world more than the blockbuster image it’s the overall maintenance of the market value....... Pfizer got approval for its two major products where in the market is very lucrative.......Tofacitinib and Eliquis are a class drug in their own way but will both these drugs be able to reach Lipitor sales status as expected....only time will say? 

J&J......will it be there in the race?

J&J is a company to watch for....being the company with one of the best credo's available till date with it vision and mission in place for more than 150 years, though there have been so many changes going around but this company has always been one of pioneers with good pipeline and products in the market. What I am still not able to understand is that why this company has not gone ahead for its biosimilar development...As everyone has joined the rat race, what is J&J going to do?

Like the other giant who have been all over the place, I though that by 2012 J&J will be part of the game and will announce but I think my hopes will not turn into reality soon.

RNAi the bubble era!!

Last decade we heard, read and wrote about RNAi technology....every one used to say we have one technology which will hit into the granular level, there were many deals which were happening in this segment, from year 2005 to 2010 there were significant number of deals in this segment but somehow the bubble has faded away....Not many companies are talking about it..Last two years I have not seen many major deals happening in this segment and some biggies have even scrapped their projects... still companies and scientists are doing research but we are still in the hope that this technology will bear some fruits in the coming years....I hope our dream turns into a reality and we have some direct hit products in the market soon in next coming 5 years........